CytomX Therapeutics Inc - Asset Resilience Ratio

Latest as of March 2026: 88.46%

CytomX Therapeutics Inc (CTMX) has an Asset Resilience Ratio of 88.46% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is CytomX Therapeutics Inc's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$317.88 Million

Cash + Short-term Investments

Total Assets

$359.36 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how CytomX Therapeutics Inc's Asset Resilience Ratio has changed over time. See how leveraged is CytomX Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down CytomX Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CytomX Therapeutics Inc stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$317.88 Million	88.46%
Total Liquid Assets	$317.88 Million	88.46%

Asset Resilience Insights

Very High Liquidity: CytomX Therapeutics Inc maintains exceptional liquid asset reserves at 88.46% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

CytomX Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare CytomX Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for CytomX Therapeutics Inc (2013–2025)

The table below shows the annual Asset Resilience Ratio data for CytomX Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	82.07%	$124.39 Million	$151.57 Million	+30.15pp
2024-12-31	51.91%	$62.57 Million	$120.53 Million	-26.06pp
2023-12-31	77.97%	$157.34 Million	$201.79 Million	+39.76pp
2022-12-31	38.21%	$99.70 Million	$260.89 Million	+8.84pp
2021-12-31	29.37%	$99.70 Million	$339.41 Million	-5.27pp
2020-12-31	34.65%	$124.26 Million	$358.66 Million	+3.08pp
2019-12-31	31.56%	$107.72 Million	$341.28 Million	-9.69pp
2018-12-31	41.25%	$188.55 Million	$457.11 Million	-8.18pp
2017-12-31	49.43%	$196.56 Million	$397.64 Million	+10.62pp
2016-12-31	38.82%	$77.29 Million	$199.13 Million	-25.52pp
2015-12-31	64.34%	$126.89 Million	$197.22 Million	+64.20pp
2014-12-31	0.14%	$100.00K	$73.06 Million	-0.57pp
2013-12-31	0.71%	$100.00K	$14.18 Million	--

pp = percentage points

About CytomX Therapeutics Inc

NASDAQ:CTMX USA Biotechnology

Market Cap

$644.40 Million

Market Cap Rank

#11146 Global

#2821 in USA

Share Price

$2.96

Change (1 day)

+1.02%

52-Week Range

$1.76 - $6.75

All Time High

$34.22